Medpage Today on MSN13d
FDA Staff Not Quite Sold on Sotagliflozin for T1D Patients With CKD
FDA staff raised familiar safety concerns about sotagliflozin as a treatment for type 1 diabetes (T1D) as the agency again ...
clinicaladvisor.com1d
FDA Panel Votes on Sotagliflozin, an Oral Treatment for Type 1 Diabetes
At a meeting of the Food and Drug Administration’s (FDA) Endocrinologic and Metabolic Drugs Advisory Committee, the majority of panel members voted against the approval of sotagliflozin (Zynquista™) ...
Hosted on MSN10d
FDA Panel Rejects SGLT1/2 Inhibitor for Type 1 Diabetes
An FDA panel on Thursday recommended against sotagliflozin as an adjunct to insulin for patients with type 1 diabetes (T1D) ...
FiercePharma11d
In FDA adcomm, Lexicon gets another thumbs down for type 1 diabetes hopeful Zynquista
On Halloween, Lexicon was haunted again as an FDA advisory committee voted 11-3 to reject Zynquista as an accompanying ...
A diabetes drug, twice rejected, stumbles again — but its developer persists
After multiple rejections, Lexicon Pharmaceuticals is inching toward an FDA decision date next month for its adjunct type 1 ...
BioSpace11d
Lexicon Loses FDA Adcomm Vote on Insulin Adjunct for Patients With Type 1 Diabetes
While an FDA advisory committee saw signals of efficacy for Lexicon Pharmaceuticals’ sotagliflozin, the panel of external ...
Lexicon announces JASN publishes sotagliflozin data
Lexicon (LXRX) announced the peer-reviewed Journal of American Society of Nephrology, or JASN, has published a research paper analyzing the ...
Optimistic Buy Rating for Lexicon Pharmaceuticals Due to Positive Outlook on Sotagliflozin’s FDA Review
H.C. Wainwright analyst Joseph Pantginis has maintained their bullish stance on LXRX stock, giving a Buy rating on October 17. Joseph ...
Yahoo Finance25d
Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe
Lexicon retains sole commercialization rights for sotagliflozin in all indications in the United States and Europe. Sotagliflozin was approved by the U.S. Food and Drug Administration in May 2023 ...